Biocon's Q2 preview highlights strong biosimilar growth, while generics face challenges amid mixed sector performance ahead of November 11 results.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback